169 related articles for article (PubMed ID: 26872889)
21. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
22. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
Welzel TM; Reddy KR; Flamm SL; Denning J; Lin M; Hyland R; Pang PS; McHutchison JG; Charlton M; Everson GT; Zeuzem S; Afdhal N
Antivir Ther; 2016; 21(6):541-546. PubMed ID: 26891418
[TBL] [Abstract][Full Text] [Related]
23. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.
Thokala P; Simpson EL; Tappenden P; Stevens JW; Dickinson K; Ryder S; Harrison P
Pharmacoeconomics; 2016 Aug; 34(8):741-50. PubMed ID: 26892974
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
Ito J; Suda G; Yamamoto Y; Nagasaka A; Furuya K; Kumagai K; Kikuchi H; Miyagishima T; Kobayashi T; Kimura M; Yamasaki K; Umemura M; Izumi T; Tsunematsu S; Sato F; Tsukuda Y; Terashita K; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
Hepatol Res; 2016 Dec; 46(13):1294-1303. PubMed ID: 26896756
[TBL] [Abstract][Full Text] [Related]
26. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
[TBL] [Abstract][Full Text] [Related]
27. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
Dahari H; Canini L; Graw F; Uprichard SL; Araújo ES; Penaranda G; Coquet E; Chiche L; Riso A; Renou C; Bourliere M; Cotler SJ; Halfon P
J Hepatol; 2016 Jun; 64(6):1232-9. PubMed ID: 26907973
[TBL] [Abstract][Full Text] [Related]
28. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Desnoyer A; Pospai D; Lê MP; Gervais A; Heurgué-Berlot A; Laradi A; Harent S; Pinto A; Salmon D; Hillaire S; Fontaine H; Zucman D; Simonpoli AM; Muret P; Larrouy L; Bernard Chabert B; Descamps D; Yazdanpanah Y; Peytavin G
J Hepatol; 2016 Jul; 65(1):40-47. PubMed ID: 26952005
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.
Zhu GQ; Zou ZL; Zheng JN; Chen DZ; Zou TT; Shi KQ; Zheng MH
Medicine (Baltimore); 2016 Mar; 95(9):e3004. PubMed ID: 26945424
[TBL] [Abstract][Full Text] [Related]
31. Direct anti-HCV agents.
Zhang X
Acta Pharm Sin B; 2016 Jan; 6(1):26-31. PubMed ID: 26904396
[TBL] [Abstract][Full Text] [Related]
32. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
33. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
Saxena V; Koraishy FM; Sise ME; Lim JK; Schmidt M; Chung RT; Liapakis A; Nelson DR; Fried MW; Terrault NA;
Liver Int; 2016 Jun; 36(6):807-16. PubMed ID: 26923436
[TBL] [Abstract][Full Text] [Related]
35. Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign.
Orkin C; Flanagan S; Wallis E; Ireland G; Dhairyawan R; Fox J; Nandwani R; O'Connell R; Lascar M; Bulman J; Reeves I; Palfreeman A; Foster GR; Ahmad K; Anderson J; Tong CY; Lattimore S
HIV Med; 2016 Mar; 17(3):222-30. PubMed ID: 26919291
[TBL] [Abstract][Full Text] [Related]
36. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
[TBL] [Abstract][Full Text] [Related]
37. Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis.
Alvarez KJ; Smaldone A; Larson EL
Curr Infect Dis Rep; 2016 Mar; 18(4):13. PubMed ID: 26915098
[TBL] [Abstract][Full Text] [Related]
38. Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.
Issa D; Eghtesad B; Zein NN; Yerian L; Cruise M; Alkhouri N; Adams R; Hanouneh IA
Int J Organ Transplant Med; 2016; 7(1):38-45. PubMed ID: 26889372
[TBL] [Abstract][Full Text] [Related]
39. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2.
Asahina Y; Izumi N; Hiromitsu K; Kurosaki M; Koike K; Suzuki F; Takikawa H; Tanaka A; Tanaka E; Tanaka Y; Tsubouchi H; Hayashi N; Hiramatsu N; Yotsuyanagi H
Hepatol Res; 2016 Feb; 46(2):129-65. PubMed ID: 26876581
[No Abstract] [Full Text] [Related]
40. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
